FCRL1 and diffuse large B-cell lymphoma: The prognostic impact of FCRL1 was further validated in progression-free survival analysis (Figure 5 and Table 7), where the log-rank test remained significant (chi-square = 4.324, p = 0.038), confirming FCRL1’s role as an independent prognostic marker in DLBCL patients.